Paste your Google Webmaster Tools verification code here

April 2014

April 2014

FDI intensifies watchful eye on Ranbaxy

The intensifying eye of FDA on the Indian units of many pharmaceutical and biotech companies has raised many eyebrows on the issue striving to figure out who is correct and who is not. The current issue talks about the same,analyzing and viewing the point of views of both the parties.

Read tete-a-tete with a start-up Theramyt, SRM University in the campus watch and Biorizon

Also read in the issue

  • 'Bio printing' assuring to be the biopromise of the future.
  • Criticism vs Biotech progress
  • Bioregulators..are you listeing?
  • Genome Editing..Let's recode our genes

Description

While Indian  Pharma industries are ridden with worries about the escalating examination and inspection by FDA, the regulator has a justification that it is the American public health which is at stake. Not one, mot two, but approximately eighteen different drug exporters in India have received warning letters in the past one year…

Features
  • BioNews
  • Rasaynika Zone
  • BioEvents
  • Readers Corner
  • & much more

subs

Most Recent Entries

  • April 2016

    April 2016

  • March 2016

    March 2016

  • February 2016

    February 2016

  • January 2016

    January 2016

2014 Powered By Wordpress, Goodnews Theme By Momizat Team